In the de novo AML subgroup, there was no statistical difference in OS according to the mutational status of DNMT3A, combined FLT3, IDH1, IDH2, and RUNX1 genes in the glasdegib + LDAC arm. This evidence concerns the gene IDH2 and acute myeloid leukemia.